期刊文献+

广州及贵州两血透中心继发性甲旁亢患病情况及危险因素分析

下载PDF
导出
摘要 目的:调查广州市中山大学附属第六医院(广州中心)及贵州省镇宁县人民医院(贵州中心)血透室维持性血透患者继发性甲旁亢(secondary hyperparathyroidism,SHPT)的患病情况及其危险因素。方法:对2016年7月1日~2016年9月30日在上述两家医院接受规律血透患者进行横断面调查,分别收集其人口学资料及临床资料,比较双中心血透患者SHPT的患病情况,用logistic回归模型对主要危险因素进行多因素分析。结果:共入组血透患者99例,其中广州中心67例,贵州中心32例,平均年龄47.0岁,男性比例65.7%。广州中心SHPT发病率为49.3%,贵州中心发病率为62.5%,双中心SHPT发病率差异无统计学意义(P=0.216)。广州中心校正钙水平更高[(2.28±0.18)mmol/L vs(1.89±0.17)mmol/L,P<0.001)],血磷水平更高[(2.17±0.59)mmol/L vs(1.42±0.52)mmol/L,P<0.001)];校正钙达标(2.1~2.5 mmol/L间)比例更高(83.6%vs 3.1%,P<0.001),高磷血症(血磷>1.78 mmol/L)比例更高(70.1%vs 21.9%,P<0.001),低钙血症(校正钙<2.1 mmol/L)比例更低(11.9%vs 96.9%,P<0.001)。logistic回归分析发现低钙血症[OR 11.33,95%CI(2.80~45.79),P=0.001],高磷血症[OR 21.94,95%CI(5.17~93.00),P<0.001]是SHPT的危险因素,而钙剂使用[OR 0.22,95%CI(0.08~0.63),P=0.005]是SHPT的保护性因素。结论:低钙高磷血症仍然是双中心血透患者发生SHPT的主要危险因素,但广州患者高磷血症突出而贵州患者低钙血症突出,钙剂的合理使用可预防SHPT的发生。
出处 《中国中西医结合肾病杂志》 2018年第6期524-526,共3页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 国家自然科学基金资助项目(No.81500552)
  • 相关文献

参考文献1

二级参考文献15

  • 1Eddington H, Hoefield R, Sinha S, et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol,2010,5 ( 12 ) :2251 - 2257.
  • 2Graciolli FG, Neves KR,dos Reis LM,et at. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental u- raemia. Nephrol Dial Transplant ,2009,24(5 ) : 1416 - 1421.
  • 3Liu H, Li X, Qin F, et al. Selenium suppresses oxidative - stress -enhanced vascular smooth muscle cell calcification by inhibi- ting the activation of the PI3K/AKT and ERK signaling path- ways and endoplasmie retieulum stress. Journal of Biological In- organic Chemistry ,2014,19 ( 3 ) :375 - 388.
  • 4Byon CH, Javed A, Dai Q,et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. Journal of Biological Chemistry, 2008,283 ( 22 ) : 15319 - 15327.
  • 5Zhao MM, Xu MJ, Cai Y, et al. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high - phosphate- induced vascular calcification in vitro and in vivo. Kidney Int,2011,79(10) :1071 - 1079.
  • 6Chavkin NW, Chia JJ, Crouthamel MH, et al. Phosphate uptake - independent signaling functions of the type III sodium - de- pendent phosphate transporter, PiT - 1, in vascular smooth mus- cle cells. Experimental Cell Research ,2015,333 ( 1 ) :39 - 48.
  • 7Yao L, Sun YT, Sun W, et al. High phosphorus level leads to aor- tic calcification via beta - catenin in chronic kidney disease. Am J Nephrol,2015,41 ( 1 ) :28 -36.
  • 8Martinez - Moreno JM, Munoz - Castaneda JR, Herencia C, et al. In vascular smooth muscle cells paricalcitol prevents phos- phate - induced Wnt/beta - catenin activation. Am J Physiol Re- nal Physiol,2012,303 (8) : F1136 - F1144.
  • 9Liu Y, Shanahan CM. Signalling pathways and vascular calcifica- tion. Front Biosci ( Landmark Ed) ,2011,16 : 1302 - 1314.
  • 10Gross P, Six I, Kamel S, et at. Vascular Toxicity of Phosphate in Chronic Kidney Disease. Circ J ,2014,78 (10) :2339 - 2346.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部